September 27,Boston, Ginkgo Bioworks Announces Collaboration with Pfizer to Focus on Discovering RNA-Based Drug Candidates. Pfizer Will LeverageGinkgo's proprietary RNA technology to drive the discovery and development of new RNA molecules in priority research areas. Ginkgo will receive an upfront payment and is eligible for research fees, development and commercial milestone payments, with a total amount of up to $331 million across three projects.GinkgoEntitled to receive potential further downstream value in the form of sales royalties.
RNA therapies that encode proteins with the potential to treat or cure diseases represent an exciting new approach in medicine, with the possibility of profound applications. Ginkgo's RNA technology integrates RNABuildBody（constructs）High-throughput screening of behaviors combined with a multi-parameter design framework to identify novel natural and synthetic elements best suited for specific applications. Ginkgo will deploy these capabilities with the goal of achieving per RNA.BuildBodyEfficient production, cyclization, increased stability, and enhanced translation. (Ginkgo Bioworks Announces Acquisition of Altar and Circularis, Stock Price Surges 12%）Dr. Will Somers, Head of Biomedical Design at Pfizer, Inc., said:"RNA therapy has been proven to be an important platform for driving global scientific innovation. With the advancement of synthetic biology, we have the potential to create new RNA therapies that can benefit patients worldwide. Utilizing Ginkgo's proprietary platform will help Pfizer discover new and exciting RNA constructs with enhanced stability and expression capabilities, leading to more effective treatments."Ginkgo Bioworks CEO and Co-founder Jason Kelly said:"Billions of patients worldwide have already benefited from advances based on RNA technology. We are excited to leverage our platform technology to harness this powerful modality and help discover and develop new drugs, with technologies designed to program RNA for maximum therapeutic effect. Ginkgo’s approach empowers our partners and accelerates discovery across diverse disease areas and modalities, where they possess deep expertise in drug development. We can’t wait to deploy our Foundry and utilize our extensive and deep RNA coding library to pioneer the era of programmable medicines together with the Pfizer team."Follow the official account below to see the world!
